Pacific Biosciences (NASDAQ:PACB) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 2 | 5 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 2 | 3 | 0 | 0 |
| 2M Ago | 1 | 0 | 1 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $4.4, a high estimate of $12.00, and a low estimate of $2.00. Experiencing a 50.56% decline, the current average is now lower than the previous average price target of $8.90.
Interpreting Analyst Ratings: A Closer Look
A comprehensive examination of how financial experts perceive Pacific Biosciences...
Login or create a forever free account to read this news
Sign up/Log in